Home / Categories / By country / Europe / Ireland / HCP - Ireland
Click to view full size image
Click here for details on how to download this file to your desktop.

Xgeva

HELP PREVENT SREs IN ADULT PATIENTS WITH BONE METASTASES FROM SOLID TUMOURS

• Bone métastasés affect many patients with advanced disease and often lead to SREs
• XGEVA is administered as a subcutaneous injection of 120mg once every 4 weeks

NICE recommended

ESMO guidelines recommend starting a bone targeted agent, XGEVA or zoledronic acid:
• in all patients with metastatic breast cancer and bone métastasés, whether they are symptomatic or not
• in patients with advanced lung cancer, renal cancer and other solid tumours who have a life expectancy more than 3 months and are considered at high risk of SREs

AMGEN Oncology

XGEVA
(denosumab)

PRECISE. PROVEN. PRACTICAL.

Other ads from this campaign

Brand: Xgeva
Country/Market: Ireland, Europe
Target: Healthcare Professional (HCP)
Tagline: Precise. Proven. Practical.
Size/duration: Single-page plus one-half of page
Publication/Aired:
Oncology News - November / December 2015


See more Xgeva ads here
Rate this file (No vote yet)
About Subscriptions Contact us Twitter LinkedIn